ALLK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -- compared to Allakos's net margin of 10.87%. Allakos's return on equity of -- beat Biogen's return on equity of 10.33%.

Allakos has a consensus price target of $0.34, signalling upside risk potential of 7.16%. On the other hand Biogen has an analysts' consensus of $197.16 which suggests that it could grow by 71.19%. Given that Biogen has higher upside potential than Allakos, analysts believe Biogen is more attractive than Allakos.

Allakos has a beta of 0.617, which suggesting that the stock is 38.32% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Allakos's net income of $376K is lower than Biogen's net income of $266.7M. Notably, Allakos's price-to-earnings ratio is -- while Biogen's PE ratio is 10.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 1.74x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Allakos's net margin of --. Allakos's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Allakos has a consensus price target of $0.34, signalling upside risk potential of 7.16%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than Allakos, analysts believe Perspective Therapeutics is more attractive than Allakos.

Allakos has a beta of 0.617, which suggesting that the stock is 38.32% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Allakos's net income of $376K is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Allakos's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -- compared to Allakos's net margin of -747.33%. Allakos's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Allakos has a consensus price target of $0.34, signalling upside risk potential of 7.16%. On the other hand Sage Therapeutics has an analysts' consensus of $8.10 which suggests that it could grow by 13.15%. Given that Sage Therapeutics has higher upside potential than Allakos, analysts believe Sage Therapeutics is more attractive than Allakos.

Allakos has a beta of 0.617, which suggesting that the stock is 38.32% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.304%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Allakos's net income of $376K is higher than Sage Therapeutics's net income of -$95.8M. Notably, Allakos's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 10.55x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -9.24%. Allakos's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

Allakos has a consensus price target of $0.34, signalling upside risk potential of 7.16%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 206.7%. Given that Vanda Pharmaceuticals has higher upside potential than Allakos, analysts believe Vanda Pharmaceuticals is more attractive than Allakos.

Allakos has a beta of 0.617, which suggesting that the stock is 38.32% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Allakos's net income of $376K is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Allakos's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 1.21x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.